Exchange: NASDAQ·Updated 07:30 PM EST

ANAB News

News
all
press releases
3 Stocks With Superb Earnings Acceleration to Buy Before 2027
AnaptysBio, Ensign Group and CEVA emerge as top earnings acceleration picks, with projected annual earnings growth of up to 913%.
Zacks
3 Stocks With Superb Earnings Acceleration to Buy Before 2027
AnaptysBio, Ensign Group and CEVA emerge as top earnings acceleration picks, with projected annual earnings growth of up to 913%.
Zacks
More News
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc bought 152,367 shares of the company's stock in a transaction on Tuesday, November 17th. The stock was purchased at an average cost of $45.66 per share, for a total transaction of $6,957,077.22. Following the completion of...
MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc acquired 138,093 shares of the stock in a transaction on Wednesday, November 18th. The stock was acquired at an average cost of $46.54 per share, for a total transaction of $6,426,848.22. Following the acquisition, the...
MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director Ecor1 Capital, Llc acquired 84,120 shares of the company's stock in a transaction that occurred on Monday, November 16th. The stock was bought at an average price of $45.66 per share, with a total value of $3,840,919.20. Following the...
MarketBeat
AnaptysBio, Inc. (ANAB) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at HC Wainwright issued their Q2 2027 earnings per share estimates for AnaptysBio in a report issued on Friday, November 13th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn $0.38 per share for...
MarketBeat
AnaptysBio (ANAB) delivered earnings and revenue surprises of -73.17% and -5.65%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
EyePoint (EYPT) delivered earnings and revenue surprises of -21.59% and +278.00%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.